Drug Trial Radar · NCT05689047
Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)
Last checked: Nov 19, 2026Latest source record: Aug 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Mar 29, 2023
Primary completion
May 28, 2024
Study completion May 28, 2024
Sponsor
- Lead sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyIndustry
- Sponsor type
- Industry
- First posted
- Jan 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the safety, efficacy, and pharmacokinetic of the combination M5717 plus pyronaridine in participants with acute uncomplicated Plasmodium falciparum malaria.
Conditions
- Acute Malaria
Interventions
M5717 330 mgDrug
Participants will receive orally 330 mg granules of M5717 in combination with pyronaridine dispersed in water under fasting condition.
M5717 500 mgDrug
Adolescent participants with weight less than (\<) 45 kilograms (kg) will receive orally 500 mg granules of M5717 in combination with pyronaridine dispersed in water once daily under fasting condition.
M5717 660 mgDrug
Adult and adolescent participants with weight more than or equal to (\>=) 45 kg will receive orally 660 mg granules of M5717 in combination with pyronaridine dispersed in water once daily under fasting condition.
Pyronaridine 360 mgDrug
Participants will receive 360 mg of pyronaridine tablets in combination with M5717 under fasting condition.
Pyronaridine 360 mgDrug
Participants with weight \>=24 to \<45 kg will receive 360 mg of tablets in combination with M5717 under fasting condition.
Pyronaridine 540 mgDrug
Participants with weight \>=45 to \<65 kg will receive 540 mg of Pyronaridine tablets in combination with M5717 under fasting condition.
Pyronaridine 720 mgDrug
Participants with weight \>=65 kg will receive 720 mg of Pyronaridine tablets in combination with M5717 under fasting condition.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort A: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Related TEAEsTime frame: Day 1 up to Day 43
- Cohort A: Number of Participants With Clinically Significant Change From Baseline in Safety Laboratory ParametersTime frame: Day 1 up to Day 29
- Cohort A: Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiogram (ECG) FindingsTime frame: Day 1 up to Day 29
- Cohort A: Number of Participants With Clinically Significant Change From Baseline in Vital SignsTime frame: Day 1 up to Day 29
- Cohort B0: Percentage of Participants With Polymerase Chain Reaction (PCR)-Adjusted Adequate Clinical and Parasitological Response (ACPR)Time frame: At Day 29
Locations
5 sites in 4 countries. Site status is shown where the registry gives one.
Institut de Recherche en Sciences de la Santé (IRSS)
Nanoro, Burkina Faso
Groupe de Recherche Action en Santé (GRAS)
Ouagadougou, Burkina Faso
Centre de Recherches Médicales de Lambaréné (CERMEL)
Lambaréné, Gabon
Centro de Investigação em saúde de Manhiça/Fundação Manhiça (CISM/FM)
Maputo, Mozambique
Infectious Diseases Research Collaboration (IDRC)
Tororo, Uganda
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.